MHRA approves Phase I/II clinical trial of IN3BIO vaccine for colorectal cancer patients
pharmafile | March 10, 2022 | News story | Business Services |
The MHRA has approved a Phase I/II clinical trial of IN3BIO’s colorectal cancer vaccine. This is the company’s second global regulatory approval for the trial.
As part of the study, IN3BIO will trial its anti-epidermal growth factor (EGF) vaccine, IN01, in combination with small molecule inhibitors (SMIs), in patients suffering from KRAS, NRAS, or BRAF mutated colorectal cancer (CRC). IN3BIO will enrol 30 subjects in two cohorts, and intends to conduct the trial in Eastern Europe, Spain, France and the UK.
The IN01 vaccine is a proprietary biological fusion molecule, designed and developed by IN3BIO. The vaccination produces antibodies which captre EGF and prevent it from binding to its target, e.g an EGF-receptor on a cell’s surface. This prevents the proliferation of tumour cells affected by EGFR mediated pathways.
Erik D’Hondt, CEO of IN3BIO, commented, “This clinical trial is aimed to establish a new standard in treating CRC patients. IN3BIO confidently launches this trial following promising data in a combination clinical trial in NSCLC patients. Based upon this encouraging data, more clinical trials are planned in 2022 with IN3BIO proprietary molecules; combination trials aiming to augment the efficacy of current TKIs and SMIs. Notably, IN3BIO’s proprietary molecule appears to enhance existing targeted treatments significantly, while appearing to be well tolerated. We are excited to progress to these clinical trials with the aim of improving patient outcomes and their treatment experience.”
IN3BIO is a UK-based biotechnology company, dedicated to developing new therapeutics that can provide cancer patients with new and effective treatments.
Lina Adams
